Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Eli Lilly submitted the orforglipron NDA to the FDA in Q1 2026 following ATTAIN Phase 3 trial data showing 14.7% body weight reduction at 45mg positioning the worlds first oral small molecule GLP-1 receptor agonist for obesity for anticipated FDA approval in late 2026 or 2027
It is not intended for human or veterinary use, diagnostic procedures, therapeutic applications, food products, dietary supplements, cosmetic formulations, or personal consumption
Youll be connected to a licensed clinician who can determine if weight loss medication is right for you and prescribe it if needed
10.1111/dom.13630 45 DonniacuoM.De AngelisA.TelescaM.BellocchioG.RiemmaM
This is typically reversible with dose reduction or discontinuation
US$ 23.37
US$ 27.64
US$ 29.67
US$ 27.94
